Later on, Barnett et al. obtained data on the TGFB1 SNP rs1800469 genotype, as well as treatment-related outcome data, and clinically-assessed fibrosis (measured at least two years after therapy) in 2782 participants from 11 patient cohorts, but their meta-analysis did not confirm previous reports of associations between fibrosis or overall toxicity and the rs1800469 SNP in breast cancer patients [7], which is consistent with our findings in our meta-analysis with further expanded sample size and improved statistical power. Here, TGFB1 is linked to breast carcinoma.